Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Escitalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.98 |
| ▸ | HTR2C | P28335 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | HRH1 | P35367 | 2/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citalopram SCHEMBL1693551 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL1118 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL1286979 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL41352 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL946 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| (R)-Citalopram SCHEMBL29414626 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL29494157 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Escitalopram SCHEMBL34948 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| Citalopram SCHEMBL3858802 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 | |
| (R)-Citalopram SCHEMBL13235283 | 0.99 | SLC6A4 (1.00) | SLC6A4MAPK1BLMPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2018-10-04 | — | — | US | claimed |
| EP-1896439-B2 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | LUNDBECK & CO AS H (DK) | 2014-10-15 | — | — | EP | claimed |
| JP-4658613-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| EP-2291177-A2 | STABLE PHARMACEUTICAL COMPOSITIONS AND THEIR PROCESSES FOR PREPARATION SUITABLE FOR INDUSTRIAL SCALE | Farmaprojects, S.A. (ES) | 2011-03-09 | — | — | EP | claimed |
| US-20110046218-A1 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | H. LUNDBECK A/S (DK) | 2011-02-24 | — | — | US | claimed |
| EP-1896439-B1 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | LUNDBECK & CO AS H (DK) | 2011-02-02 | — | — | EP | claimed |
| US-7834201-B2 | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | claimed |
| EP-2185155-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECPTOR LIGANDS | Forest Laboratories Holdings Limited (BM) | 2010-05-19 | — | — | EP | claimed |
| WO-2009135646-A2 | STABLE PHARMACEUTICAL COMPOSITIONS AND THEIR PROCESSES FOR PREPARATION SUITABLE FOR INDUSTRIAL SCALE | FARMAPROJECTS, SA (ES) | 2009-11-12 | — | — | WO | claimed |
| WO-2009020897-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-02-12 | — | — | WO | claimed |
| US-20070123584-A1 | METHOD OF TREATING PREMENSTRUAL DYSPHORIC DISORDER WITH ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2007-05-31 | — | — | US | claimed |
| US-20070021499-A1 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | H. LUNDBECK A/S (DK) | 2007-01-25 | — | — | US | claimed |
| WO-2006136169-A2 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | H. LUNDBECK A/S (DK) | 2006-12-28 | — | — | WO | claimed |
| JP-2006514952-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1578738-A1 | ESCITALOPRAM HYDROBROMIDE AND A METHOD FOR THE PREPARATION THEREOF | H. Lundbeck A/S (DK) | 2005-09-28 | — | — | EP | claimed |
| US-20050137255-A1 | Crystalline escitalopram hydrobromide and methods for preparing the same | H. LUNDBECK A/S (DK) | 2005-06-23 | — | — | US | claimed |
| WO-2005046673-A1 | A METHOD OF TREATING PREMENSTRUAL DYSPHORIC DISORDER WITH ESCITALOPRAM | LUNDBECK, H., A/S (DK) | 2005-05-26 | — | — | WO | claimed |
| US-20050101666-A1 | Method of treating premenstrual dysphoric disorder with escitalopram | H. LUNDBECK A/S (DK) | 2005-05-12 | — | — | US | claimed |
| US-20040167209-A1 | Escitalopram hydrobromide and a method for the preparation thereof | H. LUNDBECK A/S (DK) | 2004-08-26 | — | — | US | claimed |
| WO-2004056791-A1 | ESCITALOPRAM HYDROBROMIDE AND A METHOD FOR THE PREPARATION THEREOF | H. LUNDBECK A/S (DK) | 2004-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137255-A1 | Crystalline escitalopram hydrobromide and methods for preparing the same | HTR5A, SLC6A4, HTR1B | SLC6A4 2/4885MAPK1 2964/4885BLM 2537/4885 |
| US-20050101666-A1 | Method of treating premenstrual dysphoric disorder with escitalopram | SLC6A4, SLC6A3, SLC6A2 | SLC6A4 1/4885MAPK1 2669/4885BLM 3023/4885 |
| US-20070021499-A1 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | SORD, TPH1, HTR2B | SLC6A4 4/4885MAPK1 3196/4885BLM 2550/4885 |
| US-20180280405-A1 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ8 | SLC6A4 297/4885MAPK1 3079/4885BLM 1378/4885 |
| US-20040167209-A1 | Escitalopram hydrobromide and a method for the preparation thereof | SLC6A4, SLC6A2, SLC6A3 | SLC6A4 1/4885MAPK1 4578/4885BLM 3161/4885 |
| US-20110046218-A1 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE | SORD, TPH1, HTR2B | SLC6A4 4/4885MAPK1 3196/4885BLM 2550/4885 |
| US-20070123584-A1 | METHOD OF TREATING PREMENSTRUAL DYSPHORIC DISORDER WITH ESCITALOPRAM | SLC6A4, SLC6A3, SLC6A2 | SLC6A4 1/4885MAPK1 2669/4885BLM 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.